Drops end
of year 18
Drops end
of year 1
Drops end
of year 10
,23ORZHULQJFDQVWDUW
ZLWKWKHYHU\ÀUVW
GURSZLWK%$.IUHH
75$9$7$1=
6ROXWLRQ
0DQDJLQJ\RXU
SDWLHQW·V,23
EHJLQVZLWK
RQHGURS
DQGFRQWLQXHV
GURSDIWHUGURS
DIWHUGURS
Drops end
of year 5
*Based upon patient age of 60 years, dosing prostaglandin analogue once daily in both eyes for 18 years.
2
References:
1. TRAVATAN Z® Solution [package insert]. Fort Worth, TX: Alcon; 2010.
2. Heron MP, Hoyert DL, Xu JQ, et al. Deaths: Preliminary Data for 2006. National vital statistics reports;
vol 56 no 16. Hyattsville, MD: National Center for Health Statistics. 2008.
travatanz.com
©2010 Alcon, Inc. 12/10 TRV10514JA
INDICATIONS AND USAGE
TRAVATAN Z® Solution is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle
glaucoma or ocular hypertension.
DOSING AND ADMINISTRATION
One drop in the affected eye(s) once daily in the evening.
IMPORTANT SAFETY INFORMATION:
WARNINGS AND PRECAUTIONS
Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation likely to be permanent.
Eyelash changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible.
ADVERSE REACTIONS
Most common adverse reaction (30% to 50%) is conjunctival hyperemia.
USE IN SPECIFIC POPULATIONS
Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased
pigmentation following long-term chronic use.
Before prescribing TRAVATAN Z
®
Ophthalmic Solution, please read the full prescribing information.
